Inspired by the encouraging efficacy of the dual Brd4-kinase inhibitors, Burgoyne et al. recently reported a rationally designed triple-activity inhibitor that concomitantly inhibits three critical targets (namely, CDK4/6, PI3K, and BRD4) according to known synthetic lethality relationships in cancer [113]. The gene discussed is BRD4; the disease is cancer.